Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In addition, nearly 32% of people taking Zepbound lost at least a quarter of their body weight, compared to about 16% of those taking Wegovy, the study found. Weight loss was about 6% lower in men ...

Zepbound led to more long-term weight loss than Wegovy in a new clinical trial from drugmaker Eli Lilly. Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from ...

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic , a medication that is approved by the FDA to treat Type 2 diabetes but ...

In addition, nearly 32% of people taking Zepbound lost at least a quarter of their body weight, compared to about 16% of those taking Wegovy, the study found. Weight loss was about 6% lower in men ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.